<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369965</url>
  </required_header>
  <id_info>
    <org_study_id>FB-ABWT-Ⅲ-301</org_study_id>
    <secondary_id>ChiCTR-TRC-14004276</secondary_id>
    <nct_id>NCT02369965</nct_id>
  </id_info>
  <brief_title>Test Albuvirtide in Experienced Patients</brief_title>
  <acronym>TALENT</acronym>
  <official_title>Efficacy and Safety of Albuvirtide for Injection Combined With LPV/r for Treatment of HIV-1-Infected Patients Failed First-line Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frontier Biotechnologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Frontier Biotechnologies Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of albuvirtide combined with&#xD;
      lopinavir-ritonavir (LPV/r) in HIV-1-infected patients who failed first-line antiretroviral&#xD;
      therapy (ART).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a 48-week, multi-center, open-label, randomized and controlled, non-inferiority&#xD;
      phase 3 clinical trial to evaluate the safety and efficacy of albuvirtide combined with LPV/r&#xD;
      in HIV-1 infected patients who failed their first-line ART and had HIV-1 RNA levels ≥ 1000&#xD;
      copies/mL at screening.&#xD;
&#xD;
      The trial was conducted in 12 sites in China. Subjects meeting inclusion criteria were&#xD;
      randomized in a 1:1 ratio to ABT group and NRTI group, in which the ABT group received&#xD;
      albuvirtide and LPV/r combination therapy, and NRTI group received the standard 3-drug&#xD;
      regimen of LPV/r + Lamivudine (3TC) + Tenofovir (TDF). If TDF was used in the previous&#xD;
      regimen or genotypic resistance histories showed primary mutation to TDF, zidovudine (AZT) or&#xD;
      abacavir (ABC) would be used. Albuvirtide was given by weekly intravenous infusion and LPV/r&#xD;
      was given twice daily orally. A total of 418 subjects were randomized, of whom 401 received&#xD;
      at least one treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2014</start_date>
  <completion_date type="Actual">April 2, 2018</completion_date>
  <primary_completion_date type="Actual">April 2, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants of virological suppression at Week 48</measure>
    <time_frame>Through Week 48</time_frame>
    <description>Percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of viral load</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Changes of HIV-1 RNA relative to baseline at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt; 400 copies/mL at Week 48</measure>
    <time_frame>Through Week 48</time_frame>
    <description>Percentage of participants with HIV-1 RNA &lt; 400 copies/mL at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of CD4 cell count</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Changes of CD4 cell count relative to baseline at Week 48</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">418</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>albuvirtide, lopinavir-ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lopinavir-ritonavir,tenofovir,lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuvirtide</intervention_name>
    <description>albuvirtide 320mg administered intravenously once a week</description>
    <arm_group_label>albuvirtide, lopinavir-ritonavir</arm_group_label>
    <other_name>ABT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir-ritonavir</intervention_name>
    <description>lopinavir-ritonavir 400/100mg administered orally twice daily</description>
    <arm_group_label>albuvirtide, lopinavir-ritonavir</arm_group_label>
    <arm_group_label>lopinavir-ritonavir,tenofovir,lamivudine</arm_group_label>
    <other_name>Kaletra</other_name>
    <other_name>LPV/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir</intervention_name>
    <description>tenofovir 300mg administered orally once daily</description>
    <arm_group_label>lopinavir-ritonavir,tenofovir,lamivudine</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine</intervention_name>
    <description>lamivudine 300mg administered orally once daily</description>
    <arm_group_label>lopinavir-ritonavir,tenofovir,lamivudine</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 16-60 years old, male or female.&#xD;
&#xD;
          2. Those who meet the Diagnostic Criteria of AIDS and HIV Infection, the Health Industry&#xD;
             Standard of the People's Republic of China (WS 293-2008).&#xD;
&#xD;
          3. Those who have been undergoing antiretroviral treatment with nucleosides and&#xD;
             non-nucleoside reverse transcriptase inhibitors (NRTIs+NNRTIs) for at least 6 months.&#xD;
&#xD;
          4. HIV-RNA ≥ 1000 copies/mL.&#xD;
&#xD;
          5. Those who have no serious hepatic or renal functional impairment and other parameters&#xD;
             are generally in the normal ranges according to the comprehensive physical&#xD;
             examinations (including general physical examination, routine blood and urine tests,&#xD;
             blood chemistry tests, ECG, etc.).&#xD;
&#xD;
          6. The subjects should have a full understanding of the objective, nature, methods of the&#xD;
             trial and the possible reactions. He/She should participate in the trial voluntarily&#xD;
             and should sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who are in an acute stage of infection, or have suffered from AIDS-related&#xD;
             diseases (e.g. opportunistic infections or malignant tumors, etc.) at enrollment; or&#xD;
             have suffered from opportunistic infections within 3 months prior to enrollment and&#xD;
             the conditions have not reached a stable state within 2 weeks prior to enrollment.&#xD;
&#xD;
          2. Those who have used protease inhibitors or HIV fusion inhibitors for antiretroviral&#xD;
             treatment, and who have participated in HIV vaccine clinical trials or have&#xD;
             participated in other drug trials within recent 3 months.&#xD;
&#xD;
          3. Those who have been co-administered antiviral treatment for hepatitis.&#xD;
&#xD;
          4. Those whose screening test results meet one of the following: hemoglobin &lt; 9 g/dL, WBC&#xD;
             count &lt;2×109/L, neutrophil count &lt; 1×109/L, PLT count &lt; 75×109/L, transaminase &gt;&#xD;
             3×ULN, total bilirubin &gt; 2×ULN, creatinine &gt; 1×ULN, serum creatine phosphokinase &gt;&#xD;
             2×ULN.&#xD;
&#xD;
          5. Those with allergic constitution or known allergic to ingredients of the&#xD;
             investigational drug or ART drugs prescribed in the protocol.&#xD;
&#xD;
          6. Currently suffering from serious chronic diseases, metabolic diseases (such as&#xD;
             diabetes mellitus), neurological and psychiatric disorders.&#xD;
&#xD;
          7. Patients with hemophilia A or B.&#xD;
&#xD;
          8. Those with suspected or confirmed history of alcohol or drug abuse.&#xD;
&#xD;
          9. Pregnant or lactating women; or women of childbearing age who refuse to take&#xD;
             contraceptive measures during the trial.&#xD;
&#xD;
         10. Those for whom the possibility of being enrolled is low according to the judgment of&#xD;
             the investigator (e.g. weak physical condition, poor compliance, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Xie</last_name>
    <role>Study Director</role>
    <affiliation>Frontier Biotechnologies Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>302 Hospital People's Liberation Army Of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital, Capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third People'S Hospital Of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Infectious Disease Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hangzhou Xixi Hospital,Zhejiang University School Of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Zhejiang University School Of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>AIDS</keyword>
  <keyword>Albuvirtide</keyword>
  <keyword>Treatment-experienced</keyword>
  <keyword>Fusion inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

